Logo

Cenix BioScience Providing RNAi Services to Schering

Feb 28, 2005

NEW YORK, Feb. 28 (GenomeWeb News) - Cenix BioScience of Dresden, Germany is providing Schering with RNA interference research services to prioritize drug targets, Cenix said today.

 

Under two projects, which began at the end of 2004, Cenix has been validating candidate genes for drug targets provided by Schering using high-throughput RNAi and high-content phenotype analyses in human and mouse cell lines.

 

The companies disclosed neither the disease areas nor financial terms of the agreement.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.